Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP

Journal of Molecular Biology

Volumn 401, Issue 3, 2010, Pages 478-492

  Cardone, A ^a,b   Hassan, S A ^c   Albers, R W ^d   Sriram, R D ^a   Pant, H C ^d  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Cdk5; CIP; Dynamics; Kinase; Regulation

Indexed keywords

CYCLIN DEPENDENT KINASE 5; INHIBITOR PROTEIN; PROTEIN CIP; PROTEIN P25; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR; LIGAND; NERVE PROTEIN; P25 PROTEIN, HUMAN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME STABILITY; LIGAND BINDING; MOLECULAR DYNAMICS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; CHEMISTRY; HUMAN; METABOLISM; PROTEIN CONFORMATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 5; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; HUMANS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; NERVE TISSUE PROTEINS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 77955276088     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.06.040     Document Type: Article

References (39)

1. Sherr C.J., Roberts J.M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004, 18:2699.
2. Lee H.Y., Jung H., Jang J.H., Suh P.G., Ryu S.H. Cdk5 phosphorylates PLD2 to mediate EGF-dependent insulin secretion. Cell Signalling 2008, 20:1787.
3. Hisanaga S., Saito T. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 Cdk5 activator. Neurosignals 2003, 12:221.
4. Kwon Y.T., Tsai L.H. A novel disruption of cortical development in p35(-/-) mice distinct from reeler. J. Comp. Neurol. 1998, 395:510.
5. Lee M.S., Kwon Y.T., Li M., Peng J., Friedlander R.M., Tsai L.H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405:360.
6. Gong C.X., Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 2008, 15:2321.
7. Monaco E.A. Recent evidence regarding a role for Cdk5 dysregulation in Alzheimer's disease. Curr. Alzheimer Res. 2004, 1:33.
8. Maccioni R.B., Munoz J.P., Barbeito L. The molecular basis of Alzheimer's disease and other neurodegenerative disorders. Arch. Med. Res. 2001, 32:367.
9. Amin N.D., Albers R.W., Pant H.C. Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J. Neurosci. Res. 2002, 67:354.
10. Zheng Y.L., Kesavapany S., Gravell M., Hamilton R.S., Schubert M., Amin N.D., et al. A cdk5 inhibitory peptide reduces Tau hyperphosphorylation and apoptosis in neurons. EMBO J. 2005, 24:209.
11. Brown N.R., Noble M.E., Endicott J.A., Garman E.F., Wakatsuki S., Mitchell E., et al. The crystal structure of cyclin A. Structure 1995, 3:1131.
12. Brown N.R., Noble M.E., Endicott J.A., Johnson L.N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1999, 1:438.
13. Tarricone C., Dhavan R., Peng J., Areces L.B., Tsai L.H., Musacchio A. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell 2001, 8:657.
14. Volkman B.F., Lipson D., Wemmer D.E., Kern D. Two-state allosteric behavior in a single-domain signaling protein. Science 2001, 291:2429.
15. Lukin J.A., Kontaxis G., Simplaceanu V., Yuan Y., Bax A., Ho C. Quaternary structure of hemoglobin in solution. Proc. Natl Acad. Sci. USA 2003, 100:517.
16. 2+-binding protein calbindin D9k. Nat. Struct. Biol. 2000, 7:245.
17. Leo-Macias A., Lopez-Romero P., Lupyan D., Zerbino D., Ortiz A.R. An analysis of core deformations in protein superfamilies. Biophys. J. 2005, 88:1291.
18. Hindie V., Stroba A., Zhang H., Lopez-Garcia L.A., Idrissova L., Zeuzem S., et al. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. Nat. Chem. Biol. 2009, 5:758.
19. Day R.N., Nordeen S.K., Wan Y. Visualizing protein-protein interactions in the nucleus of the living cell. Mol. Endocrinol. 1999, 13:517.
20. Hamilton N. Quantification and its application in fluorescent microscopy imaging. Traffic 2009, 10:951.
21. Jolliffe I.T. Principal component analysis 2002, Springer Series in Statistics, Springer, New York, NY. 2nd edit.
22. Liu J., Kipreos E.T. Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): differential conservation of CAKs in yeast and metozoa. Mol. Biol. Evol. 2000, 17:1061.
23. Sharma P., Sharma M., Amin N.D., Albers R.W., Pant H.C. Regulation of cyclin-dependent kinases 5 catalytic activity by phosphorylation. Proc. Natl Acad. Sci. USA 1999, 96:11156.
24. Rosales J.L., Han B., Lee K.Y. Cdk7 functions as a Cdk5 activating kinase in brain. Cell Physiol. Biochem. 2003, 13:285.
25. Poon R.Y.C., Lew J., Hunter T. Identification of functional domains in the neuronal cdk5 activator protein. J. Biol. Chem. 1997, 272:5703.
26. Mapelli M., Massimiliano L., Crovace C., Seeliger M.A., Tsai L.H., Meijer L., Musacchio A. Mechanism of CDK5/p25 binding by CDK inhibitors. J. Med. Chem. 2005, 48:671.
27. Woodcock H.L., Hodoscek M., Sherwood P., Lee Y.S., Schafer H.F., Brooks B.R. Exploring the QM/MM replica path method: a pathway optimization for the chorismate to prephenate Claisen rearrangement catalyzed by chorismate mutase. Theor. Chem. Acc. 2003, 109:140.
28. Tan V.B., Zhang B., Lim K.M., Tay T.E. Explaining the inhibition of cyclin-dependent kinase 5 by peptides derived from p25 with molecular dynamics simulations and MM-PBSA. J. Mol. Mod. 2010, 16:1.
29. Brooks B.R., Brooks C.L., Mackerell A.D., Nilsson L., Petrella R.J., Roux B., et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 2009, 30:1545.
30. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005, 26:1781.
31. Hassan S.A., Mehler E.L., Weinstein H. Structure calculations of protein segments connecting domains with defined secondary structure: a simulated annealing Monte Carlo combined with biased scaled collective variables technique. Lecture Notes in Computational Science and Engineering 2002, vol. 24:197-231. Springer Verlag AG, New York, NY. K. Hark, T. Schlick (Eds.).
32. Mehler E.L., Hassan S.A., Kortagere S., Weinstein H. Ab initio computer modeling of loops in G-protein coupled receptors: lessons from the crystal structure of rhodopsin. Proteins 2006, 64:673.
33. Lay D. Linear Algebra and Its Applications 2000, Addison-Wesley, New York, NY. 2nd edit.
34. Go N., Noguti T., Nishikawa T. Dynamics of a small globular protein in terms of low-frequency vibrational modes. Proc. Natl Acad. Sci. USA 1983, 80:3696.
35. Brooks B.R., Karplus M. Harmonic dynamics of proteins: normal modes and fluctuations in bovine pancreatic trypsin inhibitor. Proc. Natl Acad. Sci. USA 1983, 80:6571.
36. Levitt M., Sander C., Stern P.S. Protein normal-mode dynamics: trypsin inhibitor, crambin, ribonuclease, and lysozyme. J. Mol. Biol. 1985, 181:423.
37. Garcia A.E. Large-amplitude nonlinear motions in proteins. Phys. Rev. Lett. 1992, 68:2696.
38. Amadei A., Linssen A.B.M., Berendsen H.J.C. Essential dynamics of proteins. Proteins 1993, 17:412.
39. Ichiye T., Karplus M. Collective motions in proteins: a covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations. Proteins 1991, 11:205-217.